Economists throw doubt on generic drug price advantage over branded version

(Medical Xpress)—People given a choice between generic or branded drugs should look closely at the ingredients in the drug they are buying, argue economists from Deakin University's Graduate School of Business.

In a paper published in the Berkeley Electronic (BE) Journal of Economic Policy and Analysis the researchers (Munirul, Vijay, Aaron and Pasquale) throw doubt on the claims by governments that the introduction of generics really does benefit consumers.

Lead researcher Dr Munirul Nabin said governments generally argued that simplifying the entry process for generic drugs increased competition in the , causing prices to fall.

"However a number of studies have shown that prices of branded drugs actually increases after generic drugs enter a market – an effect economists call the Generic Competition Paradox," he said.

Dr Nabin said theorised there were a number of reasons why the phenomena occurred, including doctors preferring to prescribe branded drugs over generics and doctors referring patients who had didn't have health insurance to generic drugs, however Deakin's analysis based on data from Canada revealed another explanation.

"It is not generic drugs vs branded drugs that is the issue, but whether the generic drugs are therapeutically equivalent to the branded variety that is the factor," he said.

Dr Nabin said put simply both generic and branded drugs had two types of ingredients, active and inactive.

"In Australia and elsewhere the in both the branded and the generic has to be biologically equivalent and there are regulatory criteria around this," he said.

"However the inactive ingredient in the branded and can differ.

"They may have different release mechanisms, dyes, pH adjusters and different salt combinations, all of which affect the stability and performance of the drug and consequently its effect on the patient.

"This nuance is well-known in the but there is a growing body of medical evidence which suggests that just because a drug is biologically equivalent, it does not make it therapeutically equivalent and thus interchangeable."

Dr Nabin said medical researchers had highlighted issues with generics, particularly for patients suffering severe illnesses such as epilepsy and depression.

"Anti-epileptic drugs and some psychotherapeutic drugs exhibit a narrow therapeutic index which makes it difficult for doctors and patients to substitute between the two varieties of drugs," he said.

"Because of this the price of branded drugs is likely to rise after the enter a market, not fall.

"To overcome this governments need to segregate drugs into their drug class when considering the effect of generic entry on price.

"If they don't they may find their health costs go up because the efficacy of the drug is not the same and more money is spent retreating patients as side-effects increase."

More information: www.degruyter.com/view/j/bejea… 4/1935-1682.3234.xml

Related Stories

First generic version of cancer drug Doxil approved

Feb 04, 2013

(HealthDay)—The first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection) has been approved by the U.S. Food and Drug Administration, which says the action should help relieve shortages ...

Professor explores generic drug effectiveness

May 27, 2013

(Medical Xpress)—It's likely if you're sick, your doctor is more inclined to prescribe a brand name drug in place of its generic equivalent. Or maybe you would rather pick up some Advil for that headache, instead of the ...

Senators push for quicker generic drug access

Jul 23, 2013

(AP)—Two senators want to do away with the agreements that pharmaceutical companies make with one another to keep lower-priced generic copies of brand-name drugs off the market.

High court weighs drug companies' generics policy

Mar 25, 2013

(AP)—The Supreme Court is struggling with whether it should stop pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.

Recommended for you

Determine patient preferences by means of conjoint analysis

11 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments